Featured
Last news
Australian telco giant slapped with $66 million fine over 'appalling' conduct
Embattled Australian telco giant Optus was hit with a $66 million fine on Wednesday over "appalling" sales conduct as the firm grapples with fallout from a network outage linked to several deaths.
Massive sinkhole in Bangkok street forces evacuations
A portion of a busy road in Thailand's capital caved in early Wednesday, leaving a hole dozens of meters deep in front of a main hospital and forcing people nearby to evacuate.
Journal retracts study linking apple cider vinegar to weight loss
An influential study claiming that drinking a small amount of apple cider vinegar every day helps people lose weight was retracted on Wednesday after an investigation found it contained multiple errors.
William E. Parker Jr.'s I Thee Wed
Beyond the Manuscript - By Evrima Chicago
David Deaton: Thrillers That Make Global Conspiracy Personal
'Beyond the Manuscript' By the Editorial Team, Evrima Chicago
Christie Sikora: Worthy, For Such a Time as This
Beyond the Manuscript By the Editorial Team, Evrima Chicago
Dr. Jozlyn Hall: Mitigation, Mercy, and the Art of Reframing Lives
Beyond the Manuscript - Evrima Chicago
Kaye Allene Allen: Faith, Resilience, and Speaking to the Next Generation
Beyond the Manuscript Evrima Chicago
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK populationThe facility marks a cornerstone of Moderna's ten-year strategic partnership with the UK Government, designed to strengthen health resilience and drive economic growth
Aytu BioPharma to Present at Upcoming September 2025 Conferences
DENVER, CO / ACCESS Newswire / September 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences:
TruMerit and EnGen Partner to Equip Foreign-Educated Health Professionals With English Skills for Success in Work and Life
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September 24, 2025 / TruMerit, a leader in global healthcare workforce development, is partnering with EnGen, a workforce-aligned English language learning solution, to support foreign-educated nurses and other healthcare professionals in building the language skills to succeed in English-speaking work environments and to flourish in their new communities.
New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine
Suitability Petition is required for shift from multidose packaging of ketamine to single-patient dose preservative free ketamineGranting of Suitability Petition enables re-filing of Abbreviated New Drug Application (ANDA) for NRx's patent-pending preservative-free ketamine product
New to The Street's Esteemed Client Aeries Technology Announces Major Enterprise Client Expansion, Projected to Reach $12M+ Annualized Run-Rate by Fiscal Year-End
Expanded, multi-function engagement validates September 4 growth plan and strengthens recurring revenue trajectory
Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition
Potential treatment for patients with breast cancer with metastasis to the brain with crofelemer would augment the significant responder analysis results for crofelemer in the prespecified subgroup of patients with breast cancer from the OnTarget study that were reported at the Multinational Association of Supportive Care in Cancer 2025 Annual Meeting and the 2024 San Antonio Breast Cancer Symposium
Ambience Healthcare Launches Real-Time HCC Compliance Validator to Reduce Audit Risk and Strengthen Documentation Integrity
SAN FRANCISCO, CA / ACCESS Newswire / September 24, 2025 / Ambience Healthcare today announced the launch of its HCC Compliance Validator. Already live with eight healthcare organizations, the HCC Compliance Validator is a real-time tool that checks whether clinician-selected diagnoses are fully substantiated according to CMS documentation standards. The tool then identifies gaps in documentation for clinicians to address before notes are completed, helping clinicians prepare audit-ready notes.
CS Diagnostics Corp. (OTCQB: CSDX) Accelerates Global Expansion with Key Regulatory Milestones and Record Growth
CHEYENNE, WY / ACCESS Newswire / September 24, 2025 / CS Diagnostics Corp. (OTCQB:CSDX) ("CSDX" or "the Company"), a pioneering leader in innovative diagnostic and protective solutions, today announced a series of transformative advancements as it resumes full-scale operations. With groundbreaking progress on its flagship products, CS-Protect Hydrogel and MEDUSA, alongside a strategic capital raise and enhanced financial reporting, CSDX is poised to capture significant market share in the U.S. and international arenas.
Medical Care Technologies Inc. Unveils AI Facial Analysis for Early Diabetes Detection
MESA, ARIZONA / ACCESS Newswire / September 24, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) announced a breakthrough in diabetes detection with its AI Facial Health Risk Estimator.
Who Is the Best Facial Feminization Surgeon in the U.S.?
Dr. Javad Sajan at Allure Esthetic is the best facial feminization surgeon in the U.S.
Wellgistics Health Launches Capital Access Program for 6,500+ Pharmacies and Supply Chain Partners, Unlocking up to $1M in Working Capital
In partnership with RxERP Financial, the program offers up to $350,000 per pharmacy and $1 million per wholesaler or manufacturer through trusted third-party financing partners, strengthening cash flow and supply chain resilience.
Medicus Pharma Ltd. To Present at Brookline Capital Markets
The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix, a next generation GnRH Antagonist as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate CancerD-MNA and Teverelix collectively represent ~$8 billion in potential market opportunity
Congress Trying to Limit Marijuana Rescheduling, but DEA Can Still Act Now
Administrator Cole, you can fight illicit drugs and build a lawful, GMP-grade cannabinoid supply chain that shrinks the black market through science. Approve qualified marijuana manufacturers and research investigators now. Patients are waiting.
Claudia Cardinale: single mother who survived rape to be a screen queen
Sixties screen siren Claudia Cardinale, who died on Tuesday aged 87, entranced audiences across the globe with the sultry gaze that made her the muse of Luchino Visconti and Federico Fellini.
Four years in prison for woman who plotted to sell Elvis's Graceland
A Missouri woman was sentenced to more than four years in prison on Tuesday for an outlandish plot to steal ownership of Graceland, the historic home of Elvis Presley, from the family of the King of Rock and Roll and put it up for auction.
Turkey facing worst drought in over 50 years
Turkey is experiencing its worst drought in over half a century, with rainfall dropping by 27 percent compared to the last three decades and even more in some regions, according to data published this week.
Denmark brands mystery drone flights 'serious' attack
Large drones that flew over Copenhagen airport for hours and caused it to shut down constituted the "most serious attack on Danish critical infrastructure" to date, Prime Minister Mette Frederiksen said Tuesday.
Drone flights 'most serious attack' on Danish infrastructure, PM says
Large drones that flew over Copenhagen airport for hours and caused it to shut down constituted the "most serious attack on Danish critical infrastructure" to date, Prime Minister Mette Frederiksen said Tuesday.
India bids tearful farewell to maverick musician
Tens of thousands of mourners thronged the streets of India's northeastern Assam state on Tuesday to bid farewell to a flamboyant artiste, celebrated as much for his music as for his irreverent persona.
Unification Church leader arrested in South Korea
The Unification Church leader was arrested Tuesday in South Korea over allegations of bribery linked to a former first lady, including luxury gifts, prosecutors said.
LiberNovo North American Pre-Sales Now Live With the First Dynamic Ergonomic Chair
From September 23 at 7:00 PM PDT through October 20, U.S. and Canadian customers can reserve Omni with an exclusive 5% new-customer discount (limited quantities) and receive a complimentary gift pack: eye mask, eco-bag, and foot cushion. Shipping begins October 20.
Viemed Healthcare Announces Completion of Share Repurchase Program
LAFAYETTE, LA / ACCESS Newswire / September 23, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader of in-home, technology-enabled post-acute respiratory care, today announced that it has completed all repurchases authorized under its previously announced share repurchase program.
Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)
Full year fiscal 2025 net revenue of $66.4 millionFull year fiscal 2025 net loss of $13.6 millionFull year fiscal 2025 adjusted EBITDA1 of $9.2 million$31.0 million cash balance at June 30, 2025Exclusive agreement in June 2025 to commercialize EXXUA™ (gepirone) extended-release tablets ("EXXUA") is expected to serve as a major growth catalyst; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market with what the Company believes to be a novel first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDDCompany to host conference call and webcast today, September 23, 2025, at 4:30 p.m. Eastern time
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2025
HILLSIDE, NJ / ACCESS Newswire / September 23, 2025 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2025.